Patents
Literature
40 results about "Mucoadhesion" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bioadhesion is the mechanism by which two biological materials are held together by interfacial forces. When relating this mechanism to the pharmaceutical sciences, mucoadhesion describes the attractive forces between a biological material and mucus or mucous membrane. Mucous membranes adhere to epithelial surfaces such as the gastrointestinal tract (GI-tract), the vagina, the lung, the eye, etc. They are generally hydrophilic as they contain many hydrogen macromolecules due to the large amount of water (approximately 95%) within its composition. However, mucin also contains glycoproteins that enable the formation of a gel-like substance. Understanding the hydrophilic bonding and adhesion mechanisms of mucus to biological material is of utmost importance in order to produce the most efficient applications. For example, in drug delivery systems, the mucus layer must be penetrated in order to effectively transport micro- or nanosized drug particles into the body.
Probiotic-polyphenol nanoparticle colon-targeted co-delivery system as well as preparation method and application thereof
PendingCN120899768AAntibacterial agentsHydroxy compound active ingredientsBiotechnologyClostridium difficile infections
The invention discloses a probiotic-polyphenol nanoparticle colon-targeted co-delivery system as well as a preparation method and application thereof, and belongs to the field of biological medicines. The FCPs and hyaluronic acid (HA) are combined through non-covalent interaction, so that the hydrogel has colon targeting property and mucosal adhesion at the same time, and delivery of probiotics is facilitated. The hydrogel (HF) based on polysaccharide has good biocompatibility, and can be used for effectively encapsulating the probiotics and the natural products. Then, the PDA-TH NPs and BA are incorporated into the polysaccharide chain network of HF, and finally the BA-HF-PDAT targeted co-delivery system is constructed. The BA (at) HF-PDAT targeted co-delivery system can protect BA from serious gastrointestinal stress, and is jointly assembled with PDT-TH NPs to realize dual slow release of thymol (Thy), so that the treatment effect of BA and Thy is improved, and the BA (at) HF-PDAT targeted co-delivery system contributes to treatment of clostridium difficile infection (CDI).
Owner:NORTHWEST A & F UNIV
Methods for treating treatment resistant depression
The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.
Owner:ATAI THERAPEUTICS INC
Chimeric protein comprising an anti-influenza virus antibody moiety and a mucoadhesive peptide fragment for preventing or treating influenza infections
ActiveUS12459988B2Antibody mimetics/scaffoldsPeptide/protein ingredientsAnti-Influenza Virus AntibodyChimera Protein
The present application provides chimeric proteins comprising an antibody moiety that specifically binds to a component of an influenza virus or a variant thereof, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating an infection caused by an influenza virus or a variant thereof in an individual.
Owner:INVISISHIELD TECHNOLOGIES LTD
Muco-adhesive, controlled release formulation of levodopa and / or esters of levodopa and uses thereof
ActiveUS12491164B2Organic active ingredientsGranular deliveryImmediate releasePharmaceutical medicine
The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains carbidopa and about 80% to 100% of the carbidopa in the oral solid formulation is present in the one or more immediate release components.
Owner:IMPAX LABORATORIES LLC
A functionalized tamarind seed polysaccharide and a preparation process thereof
PCT designated stageWO2026033304A1Organic active ingredientsCosmetic preparationsPolymer sciencePharmacy medicine
A functionalized tamarind seed polysaccharide, and a process for its preparation. In particular, said functionalized tamarind seed polysaccharide is a TSP having a selected functionalization degree and molecular weight, showing improved mucoadhesive properties, as well as stability and compatibility with pharmaceutical ingredients. Therefore, the invention also relates to a pharmaceutical composition, as well as a biomaterial, comprising said f-TSP.
Owner:FARMIGEA SPA
Compositions comprising chlorhexidine and a depigmenting complex
PCT designated stageWO2026047527A1Cosmetic preparationsToilet preparationsActive agentPhosphorylcholine
A complex consisting of lipoic acid or a salt thereof, a chelating agent such as a salt of ethylene diamine tetraacetic acid (EDTA) or analogous compounds and an ester of ascorbic acid with long-chain fatty acids, in particular ascorbyl palmitate inhibits the pigmentation of teeth induced by chlorhexidine and salts thereof. In addition to the depigmenting complex, the formulations of the invention, in the form of gels, mouthwashes, toothpastes or periodontal sprays, may contain other ingredients such as hyaluronic acid or hyaluronates, glycerophosphocholine, sweeteners, flavourings, buffering agents, viscosifying agents, mucoadhesive and filming agents, solvents, co-solvents, surfactants.
Owner:RICERFARMA
Orodispersible solid composition in the form of film for oral administration of thyroid hormones
PCT designated stageWO2025253253A1Organic active ingredientsSheet deliveryThyroid hormonesOral medication
Solid orodispersible compositions in the form of thin films for the oral administration of thyroid hormones are described, characterized by a high stability, and by the bioavailability of the active ingredient for oral absorption. The film compositions described are designed for rapid disintegration in the mouth, for sublingual administration, or to be held in the mouth for longer times before they disintegrate, but in any case without being mucoadhesive films. All the examples described are characterized by being thin and flexible and are suitable for administration even to patients who are not conscious, dysphagic or otherwise unable to swallow.
Owner:IBSA INSTITUT BIOCHIMIQUE SA
Liposome drug carrier with mucosal adhesion and its preparation method and application
ActiveCN116617405BImprove stabilityImprove adhesionOrganic active ingredientsSenses disorderEpitheliumCyclosporins
The application discloses a liposome drug carrier with mucosal adhesion, a preparation method and application thereof, and specifically, the drug carrier is DSPE-PEG-PBA, which can be used for loading cyclosporine A and crocin I, and the carrier of the application is used for loading cyclosporine A and crocin I. The liposome loaded with the two drugs has good stability and adhesion, can inhibit the side effect of cyclosporine A on the increase of ROS level, and has a wide application prospect in the treatment of inflammation and epithelial tissue damage.
Owner:SICHUAN UNIV
Bioadhesive film and methods of use thereof
A film and a method for use thereof such as for the administration of a biologically active agent or for therapy are provided. Specifically, a film, composed of a biodegradable material having a mucoadhesive surface comprising a plurality of mushroom-type structures is provided.
Owner:AZRIELI COLLEGE OF ENG JERUSALEM +1
Mucoadhesive microgel compositions and methods for using the same
Mucoadhesive microgel compositions, which include an active agent (such as HB-EGF), are provided. Aspects of the invention include a microgel comprising a crosslinked poly(ethylene glycol) methyl ether methacrylate polymer comprising a mucoadhesive functionality. Also provided are methods of making and using the mucoadhesive microgel compositions, e.g., in therapeutic applications. In one embodiment, HB-EGF loaded mucoadhesive microgel compositions are provided, e.g., for prevention or treatment of mucositis conditions, such as therapy induced oral mucositis conditions.
Owner:CENT NAT DE LA RECH SCI (C N R S) +1
Compositions and methods for preventing the spread of viruses
PCT designated stageWO2026030503A3Peptide/protein ingredientsImmunoglobulins against virusesChimera ProteinViral infection
The present application relates to compositions and methods for: (a) preventing or treating viral infections; and / or (b) preventing the transmission and / or spread of infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a virus, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating viral infections, preventing the transmission of a viral infection from an infected individual to a non-infected individual, and for preventing the spread of a viral infection within a population of individuals.
Owner:INVISISHIELD TECHNOLOGIES LTD +6
Methods of treating treatment resistant depression
PCT designated stageWO2026030301A1Nervous disorderPharmaceutical delivery mechanismDosing regimenRegimen
The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.
Owner:ATAI THERAPEUTICS INC
Modified carboxymethyl cellulose, their compositions and the uses thereof
Disclosed is a modified carboxylated polysaccharide, more particularly a modified carboxymethyl cellulose (CMC) functionalized with at least one mono-valent (M+) cation and at least one di-valent (M++) cation. Further disclosed herein is a mucoadhesive composition comprising the modified carboxymethyl cellulose (CMC) functionalized with at least one mono-valent (M+) cation and at least one di-valent (M++) cation. Further disclosed is application of the mucoadhesive composition in denture adhesives and toothpaste compositions.
Owner:ISP INVESTMENTS LLC
BIFUNCTIONAL PEPTIDE WITH MUCOADHESIVE AND VIRUS-BINDING PROPERTIES
Owner:FORSCHUNGSVERBUND BERLIN EV +1
Mucoadhesive pharmaceutical compositions of corticosteroids
Described herein are mucoadhesive pharmaceutical compositions of corticosteroids, as well as methods of making such pharmaceutical compositions, and therapeutic methods using them. The compositions typically comprise a corticosteroid in a mucoadhesive system, wherein the mucoadhesive system comprises a rheology-modifying agent and a vehicle for the corticosteroid. The compositions are particularly useful for treating inflammatory conditions of the esophagus, such as eosinophilic esophagitis, or inflammatory bowel disease.
Owner:FERRING BV
Applicator for arranging mucoadhesive surface on nasal or oral mucosa of patient and disposable component for use therewith
The present invention relates to an applicator (100) for arranging a mucoadhesive surface (202), in particular a mucoadhesive film (204) loaded with an active agent (e.g., a drug), on the nasal or oral mucosa, in particular buccal mucosa of a patient, the invention also relates to a disposable component for use with an applicator for arranging a mucoadhesive surface on a nasal mucosa or oral mucosa of a patient, and to a kit, the kit includes a disposable component having a mucoadhesive surface and an applicator for disposing the mucoadhesive surface on a nasal or oral mucosa of a patient.
Owner:IQ MEDICAL CO LTD
A nanoparticular drug delivery system with mucoadhesion properties and the synthesis method thereof
PCT designated stageWO2026024242A1Powder deliveryPharmaceutical non-active ingredientsPropanoic acidMucoadhesion
The invention relates to a nanoparticle for use as a drug carrier and the synthesis method of this nanoparticle. In the invention, magnesium / aluminium (Mg / AI) mucoadhesive thiolated layered double hydroxide (nLDHT) nanoparticles are thiolated with L-cysteine and / or thioglycolic acid and / or 2-iminothiolane hydrochloride and / or glutathione and / or N-acetyl cysteine and / or 3-mercaptopropionic acid and / or 6- mercaptohexanoic acid. Thus, nLDHT interacts with the mucin on the surface of the targeted mucosal tissue for a longer period of time and acts with fewer side effects in the target tissues.
Owner:ISTANBUL UNIVSI CERRAHPASA REKTORLUGU +1
Mucoadhesive composition for vaginal use
The present invention describes a composition for vaginal, preferably intravaginal, use for the prevention and treatment of vaginal conditions, with mucoadhesive, soothing, moisturizing and pH-regulating properties. By remaining adherent to the vaginal mucosa for prolonged periods, the composition according to the invention is therefore able to alleviate pain, burning and itching, often resulting from vaginal dryness, to promote the rebalancing of the vaginal bacterial flora, to restore the natural pH, to combat vaginal atrophy, vaginosis, vaginitis, to reduce local irritation of the tissues and to combat the proliferation of pathogens.
Owner:NIRIAL PHARMA SRL
A mucoadhesive film comprising a pharmaceutically active agent and uses thereof
PendingEP4518855A4Nervous disorderHydroxy compound active ingredientsPolymer sciencePharmacy medicine
A mucoadhesive composition and method for the administration of the pharmaceutically effective agents is provided. Specifically, a mucoadhesive composition, composed of a mucoadhesive polymer and a plurality of active agents having different water solubility embedded therewithin; and use thereof such as for the treatment of a disease is provided.
Owner:SHORT WAVE PHARMA INC
Mucoadhesive gel composition
A pharmaceutical mucoadhesive gel composition for delivering therapeutic agents (such as progesterone) by buccal, nasal, vaginal and rectal administration, thereby avoiding the hepatic first-pass metabolism. The gel composition comprises a vehicle with a gel-forming agent and a bioadhesive agent; and a therapeutic agent dispersed or suspended in the vehicle.
Owner:VIRAMAL LTD
Topical antiviral compositions comprising hyaluronic acid and carrageenan
Disclosed are topical compositions comprising hyaluronic acid or salts thereof and iota-carrageenan, preferably in a mucoadhesive matrix containing ascorbyl palmitate and choline alfoscerate. The compositions according to the invention are useful for topical treatment of Herpesvirus infections.
Owner:RICERFARMA
Muco-adhesive, controlled release formulation of levodopa and / or esters of levodopa and uses thereof
The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa.
Owner:IMPAX LABORATORIES LLC
MUCOADHESIVE LEVODOPA CONTROLLED RELEASE FORMULATIONS AND / OR LEVODOPA ESTERS AND USES THEREOF
Owner:IMPAX LABORATORIES LLC BRIDGEWATER
Sublingual patch
PCT designated stageWO2026052569A1Pharmaceutical delivery mechanismMacromolecular non-active ingredientsPharmaceutical drugAqueous solubility
The invention relates to formulations for water-insoluble active pharmaceutical ingredients. More particularly, the invention relates to a mucoadhesive patch consisting of a first layer consisting of a mucoadhesive film and a second layer consisting of a self-emulsifying drug delivery system (SEDDS) lipid microstructure for delivery of a poor water-soluble active pharmaceutical ingredient or a water insoluble active pharmaceutical ingredient.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
A mucoadhesive layer for buccal administration of an active pharmaceutical ingredient
PCT designated stageWO2026093519A1Pharmaceutical non-active ingredientsSheet deliveryBuccal usePharmacy medicine
The present invention relates to a mucoadhesive layer for buccal administration of an active pharmaceutical ingredient (API), and to a method of preparing such mucoadhesive layer. Moreover, the present invention also relates to a mucoadhesive film comprising a mucoadhesive layer for buccal administration of an active pharmaceutical ingredient, and to a method of preparing such mucoadhesive film.
Owner:IQ MEDICAL GMBH
Recombinant lactococcus lactis microcapsule as well as preparation method and application thereof
The invention discloses a recombinant lactococcus lactis microcapsule as well as a preparation method and application thereof, and belongs to the field of gene engineering. In order to solve the technical problems that in the prior art, a method for treating or relieving inflammatory bowel diseases is low in safety, high in side effect, unstable in curative effect and insufficient in targeting property, the invention provides a recombinant lactococcus lactis microcapsule. Constructing recombinant lactococcus lactis with an antioxidant function; the recombinant lactococcus lactis microcapsule with antioxidant enzyme expression ability and a nano protective coating is obtained by coating the recombinant lactococcus lactis with a mucosa adhesive chitosan and sodium alginate composite nano material. The recombinant lactococcus lactis microcapsule provided by the invention can improve the activity of an oral delivery substance in a severe acidic environment of gastrointestinal tracts and complex physiological barrier conditions, improves the bioavailability, and provides a new strategy and an experimental basis for clinical prevention and treatment of inflammatory bowel diseases.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY
Mucoadhesive composition comprising chios mastic
PCT designated stageWO2026028122A1Organic active ingredientsAerosol deliveryOral mucous membraneBuccal use
The present invention relates to the formulation of innovative pharmaceutical compositions for buccal use for use in the treatment and prevention of mucocutaneous diseases of the oral cavity. Said pharmaceutical compositions are able to resist salivary re-washing and have a high substantivity on the oral mucous membranes, obtaining a massive topical effect with the minimum possible systemic assimilation.
Owner:UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA
Carbon-based nano material for relieving ischemia reperfusion injury
The invention discloses a carbon-based nano material for relieving ischemia reperfusion injury, and relates to the technical field of medical chemistry application. The carbon-based nano material comprises an active component and a pharmaceutically acceptable carrier, the active component is at least one of fullerene, fullerol, carbon quantum dots, carbon fibers, carbon nanotubes, carbon nanowires and graphene; the pharmaceutically acceptable carrier is at least one of water, cellulose, acrylic resin, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, a polyoxyethylene-polyoxypropylene copolymer and a derivative thereof, hyaluronic acid and a derivative thereof, alginic acid and a derivative thereof, and chitosan and a derivative thereof. The invention also provides a preparation method and application of the carbon-based nano material. By utilizing the pH response characteristic of the alginate microspheres, the fullerol is accurately released in the small intestine, and meanwhile, by virtue of the mucosa adhesion property of the chitosan, the retention time of the fullerol in the small intestine is prolonged, and the slow release of the medicine is realized.
Owner:成都医学院第一附属医院
System for oral delivery of active ingredients
The present invention relates to a system for oral delivery of an active ingredient, the system comprising a mucosal adhesion layer and a backing layer containing the active ingredient.
Owner:PHILIP MORRIS PRODUCTS SA
Sublingual patch
PCT designated stageWO2026052569A8Pharmaceutical delivery mechanismMacromolecular non-active ingredientsPharmaceutical drugAqueous solubility
The invention relates to formulations for water-insoluble active pharmaceutical ingredients. More particularly, the invention relates to a mucoadhesive patch consisting of a first layer consisting of a mucoadhesive film and a second layer consisting of a self-emulsifying drug delivery system (SEDDS) lipid microstructure for delivery of a poor water-soluble active pharmaceutical ingredient or a water insoluble active pharmaceutical ingredient.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)